Anvisa could not give details on what happened because of privacy regulations (Representational)
Brazil's health regulator said Monday it had suspended clinical trials of a Chinese-developed Covid-19 vaccine after an "adverse incident" involving a volunteer recipient, a blow for one of the most advanced vaccine candidates.
The regulator, Anvisa, said in a statement that it had "ruled to interrupt the clinical trial of the CoronaVac vaccine after a serious adverse incident" on October 29.
It said it could not give details on what happened because of privacy regulations, but that such incidents included death, potentially fatal side effects, serious disability, hospitalization, birth defects and other "clinically significant events."
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)